Novo Nordisk's Pill Approval as a Catalyst to Defend Market Share

28 days ago

Caroline Hepka

"There is one stock in Europe that is really surging today and that is Novo Nordisk. Investors salivating over a a new drug, a new advance indeed. Yeah. Kind of the one big story before uh the Christmas little fully kicks in. Uh but as you say, yes. So Novo Nordisk has won approval to sell a pill version of its weavi uh blockbuster obesity drug that's in the US and sale should start in January. And the reason that this is really boosting shares, shares are up about 7% and they've been holding those gains all through the morning is because it's a a real crucial step to try and defend uh it's market share essentially from US rival Eli Liy."

Novo Nordisk has won regulatory approval to sell a pill version of its blockbuster obesity drug, slated to begin sales in January. This move is viewed as a crucial step to defend market share from its US competitor, with shares already up about 7% in early trading.

Related Stocks